The Trendy Research On Peptide BPC-157 That Has Scientists Concerned

If you are a viewer of fitness content, you might have heard of peptide blends like "Wolverine" and "Glow." Both of these contain the peptide body protection compound-157 (BPC-157), which has grown in popularity with its promises of healing, similar to the super-powered abilities of the comic book hero Wolverine. However, there are no strong clinical studies that support this treatment, nor are there studies that investigate its potential risks to humans. So, how are people getting their hands on this, and what dangers are posed by such unregulated access?

BPC-157 is a peptide that naturally occurs within the body to promote gastrointestinal homeostasis. Due to its potential uses in bone and skeletal muscle healing, some studies have been performed in non-human animals and yielded promising results. However, a comprehensive review published in 2025 revealed that only one clinical trial had been conducted to study its effects in humans. Moreover, it was a very poorly designed study with no control groups, based solely on surveys conducted over the phone.

As of writing, the Food and Drug Administration (FDA) includes BPC-157 in its list of bulk substances that pose significant safety risks, stating that there is insufficient information to suggest whether it is harmful to humans. However, a loophole to list it as "for research purposes only" allows BPC-157 to continue being sold, where it can be used by people who appear to be open to the idea of experimenting on themselves. Further, the companies that sell BPC-157 aren't bound by the regulatory processes and rigorous testing required of traditional pharmaceutical companies.

By design, clinical testing is incredibly thorough and typically takes 6 to 10 years to complete. There are three phases of tests in humans before a drug can be eligible for FDA approval. The goal of the first phase is to establish safety and starts with a small number of research participants (between 20 and 100). Approximately 70% of drugs make it past this phase, and it lasts for several months. During phase two, researchers further investigate the efficacy and potential side effects of the medication, and it can last up to two years, with only one-third of drugs proceeding beyond this phase. Finally, the third phase involves up to 3,000 participants and monitors them for adverse effects, lasting 1–4 years. Additionally, a fourth phase will often be undertaken in order to observe the effects of the medication after initial FDA approval.

For reference, the only human study of BPC-157 to date included just 17 participants, with 12 of those receiving a BPC-157 injection alone. This sample size can't provide anywhere near enough information to determine whether this peptide is safe, much less whether it is even effective. One safety concern regarding BPC-157 is its potential to increase the risk of cancer. Because this peptide, as with many research peptides that have garnered attention, is meant to promote cell growth, and cancer involves the unrestricted growth of cells, its use could theoretically contribute to the proliferation of precancerous cells.

These risks, of course, only apply if what you're injecting is actually BPC-157. Due to the comparative lack of oversight on these research peptides, the concentration, purity, and even overall contents are in question. Without being held to the rigorous standards of FDA-approved pharmaceuticals, people risk exposing themselves to contaminated products. Moreover, given the rapid breakdown of these peptides, injection is often the only viable mode of administration. This requires access to sterile equipment, like saline and syringes. Because people can use BPC-157 without consulting their physician, they might not know how or have access to the tools required to safely perform these injections at home. Importantly, unsafe injection practices lead to a higher risk of bloodborne pathogens.

Although the FDA currently warns against BPC-157 use, Robert F. Kennedy Jr., the Secretary of Health and Human Services (the agency that oversees the FDA), has promised to reduce existing restrictions. Though Kennedy has promoted the use of experimental peptides, he has no background in research and a rich history of touting pseudoscience.

Physicians have cautioned against loosening FDA restrictions, emphasizing that the data are not sufficient to support the efficacy or safety of research peptides like BCP-157 in humans. Additionally, there is no consensus on the proper dosage for these types of chemicals. Lifting the ban currently imposed by the FDA prevents the necessary clinical trial steps — which determine proper dosages and protect public health — from being taken, thereby imposing unnecessary risk on individuals.